/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

M

Mattia Cremona

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

90

Papers

1.1K

Citations

17

h-index

29

i10-index

Mattia Cremona is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Colorectal Cancer Treatments and Studies & Cancer, Lipids, and Metabolism. The author has an h-index of 17, co-authored 77 publications.

ORCID: 0000-0003-3000-6246

Research Topics

HER2/EGFR in Cancer Research Colorectal Cancer Treatments and Studies Cancer, Lipids, and Metabolism Monoclonal and Polyclonal Antibodies Research Cancer Genomics and Diagnostics

Papers by this author

works

A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib

2014 · Breast Cancer Research and Treatment · 49 citations

https://doi.org/10.1007/s10549-014-3239-5

Naomi Elster Mattia Cremona Clare Morgan Sinéad Toomey

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

2019 · Cancer Cell International · 44 citations

https://doi.org/10.1186/s12935-019-0725-1

Marta Llauradó Fernández Amy Dawson Joshua Hoenisch Hannah Kim

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)

2018 · PLoS ONE · 22 citations

https://doi.org/10.1371/journal.pone.0200996

Damien Côté Alex J. Eustace Sinéad Toomey Mattia Cremona

Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro

2018 · BMC Cancer · 21 citations

https://doi.org/10.1186/s12885-018-4035-0

Ozlem Aslan Mattia Cremona Clare Morgan Lydia W.T. Cheung

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer

2016 · Oncotarget · 20 citations

https://doi.org/10.18632/oncotarget.12782

Sinéad Toomey Stephen F. Madden Simon J. Furney Yue Fan

Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A

2020 · Investigational New Drugs · 17 citations

https://doi.org/10.1007/s10637-020-00937-y

Laura Breen Patricia Gaule Alexandra Canonici Naomi Walsh

Research topics

topics

HER2/EGFR in Cancer Research

Colorectal Cancer Treatments and Studies

Cancer, Lipids, and Metabolism

Monoclonal and Polyclonal Antibodies Research

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat